drugset / Trial / NCT03938740

Comparison of Different Insulin Dosing Algorithms Using Hepatic Directed Vesicle-Insulin Lispro and Insulin Degludec

NCT03938740

Phase 2 Completed 61 enrolled Diasome Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

Multi-center, open-label, multiple dose safety, tolerability and efficacy study

Timeline

Start
2019-03-18
Primary completion
2019-12-06
Completion
2020-03-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Lispro Protein / enzyme biologic
Subject insulin degludec Protein / enzyme biologic